Get the Stockscreener App
115.22
0.14%
0.16
After Hours:
115.22
Neurocrine Biosciences Inc stock is traded at $115.22, with a volume of 871.85K.
It is up +0.14% in the last 24 hours and down -9.32% over the past month.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
See More
Previous Close:
$115.06
Open:
$115.24
24h Volume:
871.85K
Relative Volume:
0.97
Market Cap:
$11.57B
Revenue:
$2.12B
Net Income/Loss:
$339.20M
P/E Ratio:
61.95
EPS:
1.86
Net Cash Flow:
$494.60M
1W Performance:
-2.15%
1M Performance:
-9.32%
6M Performance:
-16.46%
1Y Performance:
+2.42%
1-Day Range:
$114.12
$115.90
1-Week Range:
$114.08
$117.89
52-Week Range:
$103.63
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight - PR Newswire
Neurocrine touts long-term effectiveness of Ingrezza for Huntington's disease chorea - Seeking Alpha
Neurocrine reports sustained Huntington's chorea treatment effects - Investing.com
NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan
Neurocrine Biosciences (NBIX) Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use - StreetInsider.com
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use - PR Newswire
Perceptive Advisors LLC Cuts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 7,326 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Thrivent Financial for Lutherans Has $6.41 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Sei Investments Co. Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Pacer Advisors Inc. Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Integral Health Asset Management LLC Sells 80,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Increased by Ensign Peak Advisors Inc - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Intech Investment Management LLC - MarketBeat
Simplify Asset Management Inc. Buys New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit - StockTitan
28% Of This Neurocrine Biosciences Insider's Holdings Were Sold - Simply Wall St
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by American Century Companies Inc. - MarketBeat
RSI Alert: Neurocrine Biosciences (NBIX) Now Oversold - Nasdaq
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Primecap Management Co. CA - MarketBeat
Neurocrine Biosciences executive sells over $420k in company stock By Investing.com - Investing.com Australia
Neurocrine Biosciences executive sells over $420k in company stock By Investing.com - Investing.com Canada
Neurocrine Biosciences executive sells over $420k in company stock - Investing.com
Neurocrine Biosciences executive sells over $420k in company stock By Investing.com - Investing.com UK
Neurocrine Biosciences To Present At Cantor Global Healthcare Conference; Webcast At 3:05 PM ET - Nasdaq
Edgestream Partners L.P. Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Reaffirmed by Cantor Fitzgerald - MarketBeat
Renaissance Technologies LLC Has $339.79 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Third gene therapy development candidate nominated under Voyager and Neurocrine collaboration - BioWorld Online
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected - StockTitan
Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected - GlobeNewswire
Dai ichi Life Insurance Company Ltd Has $6.67 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock - Insider Monkey
Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock - Yahoo Finance
Cornercap Investment Counsel Inc. Invests $1.22 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint - Benzinga
Neurocrine Scraps Schizophrenia Candidate After Phase II Failure - BioSpace
Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint - Clinical Trials Arena
Neurocrine halts luvadaxistat development after trial miss - Investing.com
Neurocrine halts development of schizophrenia drug as trial fails - Reuters
Neurocrine halts development of schizophrenia drug as trial fails - AOL
Neurocrine ending development of luvadaxistat amid failed study (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences's Schizophrenia Treatment Misses Endpoint - MarketWatch
Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat - StreetInsider.com
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia - Kilgore News Herald
Levodopa-induced Dyskinesia Market Growth Anticipated by 2032 - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Savant Capital LLC - MarketBeat
Analysts Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $162.20 - MarketBeat
Rice Hall James & Associates LLC Reduces Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Huntington's Disease Market Forecasted to Surge in Coming - openPR
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):